Ardelyx (NASDAQ:ARDX) Director David Mott Buys 333,333 Shares of Stock

Ardelyx, Inc. (NASDAQ:ARDX) Director David Mott bought 333,333 shares of the business’s stock in a transaction on Friday, February 20th. The shares were acquired at an average cost of $5.84 per share, for a total transaction of $1,946,664.72. Following the purchase, the director directly owned 3,302,918 shares in the company, valued at $19,289,041.12. This represents a 11.22% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Ardelyx Trading Up 0.3%

NASDAQ:ARDX opened at $5.75 on Tuesday. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -23.00 and a beta of 0.57. The company has a debt-to-equity ratio of 1.21, a quick ratio of 4.11 and a current ratio of 4.31. Ardelyx, Inc. has a 1 year low of $3.21 and a 1 year high of $8.40. The business has a fifty day moving average of $6.76 and a 200-day moving average of $6.13.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.03). The company had revenue of $125.22 million during the quarter, compared to analyst estimates of $118.04 million. Ardelyx had a negative return on equity of 40.63% and a negative net margin of 15.12%.The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.02 EPS. Equities analysts predict that Ardelyx, Inc. will post -0.18 earnings per share for the current year.

Institutional Investors Weigh In On Ardelyx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its holdings in shares of Ardelyx by 23.1% during the 4th quarter. Invesco Ltd. now owns 317,410 shares of the biopharmaceutical company’s stock valued at $1,851,000 after acquiring an additional 59,597 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its position in Ardelyx by 4.7% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 38,512 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 1,722 shares during the last quarter. Mackenzie Financial Corp grew its stake in Ardelyx by 12.8% in the fourth quarter. Mackenzie Financial Corp now owns 199,550 shares of the biopharmaceutical company’s stock valued at $1,155,000 after purchasing an additional 22,715 shares in the last quarter. NewEdge Advisors LLC increased its position in Ardelyx by 1,690.9% in the 4th quarter. NewEdge Advisors LLC now owns 17,909 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 16,909 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Ardelyx during the 4th quarter worth about $698,000. Hedge funds and other institutional investors own 58.92% of the company’s stock.

Key Headlines Impacting Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Director David M. Mott purchased 333,333 shares (~$1.95M) at about $5.84, increasing his stake by ~11.2% — a strong insider vote of confidence that can support the stock. SEC Filing: Director Purchase
• Positive Sentiment: Wedbush reaffirmed an “outperform” rating and set a $19 price target (large upside vs. current levels), which can attract buyers and boost sentiment. Wedbush Note via Benzinga
• Positive Sentiment: Other firms reiterated bullish views (BTIG buy rating; HC Wainwright optimistic on FY2026 earnings), reinforcing analyst support that can sustain buying interest. BTIG Reiteration HC Wainwright Note
• Neutral Sentiment: Quarterly revenue beat estimates ($125.2M vs. $118.0M) and year-over-year revenue growth of ~7.8% — a constructive fundamental datapoint, though offset by an EPS miss. (Earnings release was on Feb 19.)
• Negative Sentiment: Earnings EPS missed expectations (reported a loss vs. small expected profit), which triggered a sell-off (shares were reported down ~10.4% after the earnings release). EPS misses typically pressure sentiment and can lead to continued volatility. Earnings Reaction
• Negative Sentiment: Multiple insiders — including the CEO, CFO and several executives — sold shares on Feb 20 (notably the CEO sold ~45,982 shares). Clustered insider selling can be read as profit-taking or reduced insider conviction and may weigh on sentiment. (These sales occurred near $5.85.) SEC Filing: CEO Sale

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ARDX shares. Raymond James Financial reaffirmed a “strong-buy” rating and set a $19.00 price target on shares of Ardelyx in a research note on Thursday, January 8th. HC Wainwright upped their price objective on Ardelyx from $10.00 to $18.00 and gave the company a “buy” rating in a report on Friday. Citigroup lifted their target price on Ardelyx from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Wedbush reiterated an “outperform” rating and issued a $19.00 price target on shares of Ardelyx in a research report on Monday. Finally, BTIG Research restated a “buy” rating and set a $17.00 price objective on shares of Ardelyx in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $15.09.

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.